Search details
1.
Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study.
Gastroenterology
; 153(5): 1240-1250.e2, 2017 11.
Article
in English
| MEDLINE | ID: mdl-28760384
2.
Independent data monitoring committees: preparing a path for the future.
Am Heart J
; 168(2): 135-41.e1, 2014 Aug.
Article
in English
| MEDLINE | ID: mdl-25066551
3.
Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial.
Nat Med
; 28(1): 89-95, 2022 01.
Article
in English
| MEDLINE | ID: mdl-34873344
4.
Development and psychometric evaluation of the Diabetic Gastroparesis Symptom Severity Diary.
Clin Exp Gastroenterol
; 12: 93-103, 2019.
Article
in English
| MEDLINE | ID: mdl-30863134
5.
Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active-control trial with glimepiride.
Diab Vasc Dis Res
; 5(3): 168-76, 2008 Sep.
Article
in English
| MEDLINE | ID: mdl-18777489
6.
Treatment With a Ghrelin Agonist in Outpatient Women With Anorexia Nervosa: A Randomized Clinical Trial.
J Clin Psychiatry
; 79(1)2018.
Article
in English
| MEDLINE | ID: mdl-29325236
7.
Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment.
J Clin Endocrinol Metab
; 103(7): 2601-2612, 2018 07 01.
Article
in English
| MEDLINE | ID: mdl-29726959
8.
MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency.
Nat Med
; 24(5): 551-555, 2018 05.
Article
in English
| MEDLINE | ID: mdl-29736023
9.
Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
Diabetes Care
; 29(5): 1016-23, 2006 May.
Article
in English
| MEDLINE | ID: mdl-16644631
10.
The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults.
AIDS
; 18(16): 2137-44, 2004 Nov 05.
Article
in English
| MEDLINE | ID: mdl-15577646
11.
Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial.
Am J Med
; 116(4): 223-9, 2004 Feb 15.
Article
in English
| MEDLINE | ID: mdl-14969649
12.
Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study.
Clin Ther
; 24(9): 1401-13, 2002 Sep.
Article
in English
| MEDLINE | ID: mdl-12380632
13.
Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study.
Clin Ther
; 24(9): 1426-38, 2002 Sep.
Article
in English
| MEDLINE | ID: mdl-12380634
14.
A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes.
Postgrad Med
; 122(3): 16-27, 2010 May.
Article
in English
| MEDLINE | ID: mdl-20463410
15.
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
Diabetes Care
; 32(4): 650-7, 2009 Apr.
Article
in English
| MEDLINE | ID: mdl-19114612
16.
Coadministration of muraglitazar plus glyburide: improvement of glycaemic and lipid profiles in patients with type 2 diabetes.
Diab Vasc Dis Res
; 6(2): 120-32, 2009 Apr.
Article
in English
| MEDLINE | ID: mdl-20368202
17.
Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes.
Diab Vasc Dis Res
; 6(3): 205-15, 2009 Jul.
Article
in English
| MEDLINE | ID: mdl-20368213
18.
A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment.
Diabetes Care
; 32(9): 1656-62, 2009 Sep.
Article
in English
| MEDLINE | ID: mdl-19528367
19.
Do we need to adjudicate major clinical events?
Clin Trials
; 5(1): 56-60, 2008.
Article
in English
| MEDLINE | ID: mdl-18283081
Results
1 -
19
de 19
1
Next >
>>